Loading...
XCNQ
DOSE
Market cap17mUSD
Jul 22, Last price  
0.19CAD
1D
-2.56%
1Q
2.70%
IPO
-76.25%
Name

Rapid Dose Therapeutics Corp

Chart & Performance

D1W1MN
P/E
P/S
24.12
EPS
Div Yield, %
Shrs. gr., 5y
10.84%
Rev. gr., 5y
%
Revenues
1m
+42.06%
00000000000101,498262,8051,751,916718,2981,020,424
Net income
-4m
L+12.98%
-3,379-6,805-79,956-67,720-178,548-19,488-19,202-51,744-47,097-50,079-11,398,345-8,163,860-2,440,215-12,548,376-3,811,635-4,306,500
CFO
-2m
L+165.65%
-35,442-36,364-44,924-55,760-160,184-28,879-58,294-49,129-30,655-57,991-2,132,258-3,032,681-1,623,642-2,999,529-863,917-2,294,991

Profile

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.
IPO date
Dec 17, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑022023‑022022‑022021‑022020‑022019‑022017‑092016‑092015‑09
Income
Revenues
1,020
42.06%
718
-59.00%
Cost of revenue
3,483
3,619
Unusual Expense (Income)
NOPBT
(2,463)
(2,901)
NOPBT Margin
Operating Taxes
2
Tax Rate
NOPAT
(2,463)
(2,902)
Net income
(4,306)
12.98%
(3,812)
-69.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,205
152
BB yield
-6.56%
Debt
Debt current
329
1,395
Long-term debt
2,154
580
Deferred revenue
Other long-term liabilities
Net debt
2,322
1,948
Cash flow
Cash from operating activities
(2,295)
(864)
CAPEX
1
Cash from investing activities
Cash from financing activities
2,428
857
FCF
(2,818)
(418)
Balance
Cash
161
28
Long term investments
Excess cash
110
Stockholders' equity
(12,626)
(9,823)
Invested Capital
11,922
8,764
ROIC
ROCE
349.72%
273.92%
EV
Common stock shares outstanding
104,964
103,416
Price
0.18
 
Market cap
18,369
 
EV
20,690
EBITDA
(1,843)
(2,273)
EV/EBITDA
Interest
661
265
Interest/NOPBT